δ-Opioid receptor as a potential therapeutic target for ischemic stroke

Kalpana Subedi1, Hongmin Wang1

  • 1Division of Basic Biomedical Sciences and Center for Brain and Behavior Research, Sanford School of Medicine, University of South Dakota, Vermillion, SD, USA.

Neural Regeneration Research
|September 20, 2019
PubMed

Insights

Activation of the delta-opioid receptor shows promise for treating ischemic stroke neuronal injury. This approach may also help prevent dementia and Alzheimer's disease linked to stroke by modulating key proteins.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neurology

Background:

  • Ischemic stroke is a major global health issue causing brain damage due to reduced blood flow.
  • Current treatments for ischemic stroke have limitations, leaving many patients without effective options.
  • Neuronal injury following stroke necessitates novel therapeutic strategies.

Purpose of the Study:

  • To review recent research on activating the delta-opioid receptor (DOR) for treating ischemic stroke-induced neuronal injury.
  • To explore the potential of DOR activation in mitigating stroke-related dementia and Alzheimer's disease.
  • To discuss the role of DOR agonists in modulating amyloid precursor protein and beta-secretase activity.

Main Methods:

  • Literature review of preclinical and clinical studies on DOR activation in ischemic stroke models.
  • Analysis of research investigating the effects of non-peptidic DOR agonists on neuronal survival and function.
  • Examination of studies exploring the impact of DOR modulation on amyloid precursor protein processing and beta-secretase activity.

Main Results:

  • Activation of DOR demonstrates neuroprotective effects against ischemic injury in the brain.
  • Non-peptidic DOR agonists show potential for therapeutic intervention in stroke recovery.
  • DOR activation influences pathways relevant to Alzheimer's disease pathogenesis, including amyloid precursor protein metabolism.

Conclusions:

  • Delta-opioid receptor activation represents a promising therapeutic strategy for acute ischemic stroke.
  • Targeting DOR may offer a dual benefit by addressing both acute neuronal injury and long-term cognitive decline post-stroke.
  • Further research into DOR agonists could lead to novel treatments for stroke and associated neurodegenerative conditions.

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
4.1K
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.5K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.0K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.1K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.6K